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showing cytological atypia, increased mitotic activity, 
increased cellularity and an unstructured growth pattern, 
the term “poorly differentiated chordoma” has been coined 
[2, 7]. Interestingly, poorly differentiated chordomas are 
not only associated with an aggressive clinical course and 
high mortality [2], but also with loss of SMARCB1 expres-
sion [7, 10]. Loss of SMARCB1 (also known as hSNF5/
INI1), a core member of the SWI/SNF chromatin remod-
eling complex, is the hallmark of atypical teratoid/rhabdoid 
Chordomas are tumors of the skull base and spine thought 
to arise from remnants of the notochord. Expression of 
cytokeratins and S100 is frequent and nuclear expression 
of brachyury, a transcription factor important for axial 
development, has been shown to be a sensitive and fairly 
specific diagnostic marker [6]. For pediatric chordomas 
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tumor (AT/RT), a brain tumor in young children also dem-
onstrating a highly aggressive biological behavior. Since 
AT/RT invading the skull and even clival location are on 
record [4, 9], it remains uncertain if poorly differentiated 
chordoma represents a distinct entity or part of the AT/RT 
spectrum instead. Here we show that poorly differentiated 
chordoma can be clearly distinguished not only from AT/
RT, but also from conventional chordoma by DNA meth-
ylation profiling.
Formalin-fixed paraffin embedded samples of seven 
poorly differentiated chordomas (including four previously 
reported cases [1, 7]) were retrieved from our archives. In 
addition to the primary tumors, in one case material from a 
recurrence could be examined. Data on treatment and over-
all survival were compiled by reviewing patient records. 
For comparison, samples of 14 conventional chordomas 
as well as ten AT/RT of each of three recently described 
molecular subgroups (i.e. TYR, MYC and SHH) [3] were 
evaluated. Protein expression of brachyury and SMARCB1 
was examined using immunohistochemistry. Fluores-
cence in situ hybridization (FISH) of the SMARCB1 locus, 
SMARCB1 sequencing and multiplex ligation-dependent 
probe amplification (MLPA) using the SALSA MLPA 
P258 (SMARCB1) kit (MRC-Holland) were performed in 
tumors showing SMARCB1 loss. All samples were ana-
lyzed using the Illumina Infinium Human Methylation 
450k Bead Chip (see supplemental methods).
The median age of the four boys and three girls harbor-
ing poorly differentiated chordomas was 7 years (range 
1–11 years; for details see supplementary Table 2). The 
median overall survival was only 9 months (95 % con-
fidence interval of 6–12 months). On histopathological 
examination, all poorly differentiated chordomas and con-
ventional chordomas exhibited nuclear brachyury expres-
sion, and nuclear brachyury expression was also observed 
in 2/30 AT/RT (Fig. 1b). In contrast, all poorly differenti-
ated chordomas and AT/RT showed loss of SMARCB1 
expression, while SMARCB1 expression was retained in 
conventional chordomas. Unsupervised clustering analy-
sis of the 52 methylation profiles using the 5000 most 
differentially methylated CpG sites across all samples 
identified five distinct methylation groups, including two 
distinct chordoma clusters, representing the poorly dif-
ferentiated chordomas and the conventional chordomas, 
respectively, both clustering apart from the three molecu-
lar AT/RT subgroups (Fig. 1a). Copy number profiles were 
derived from intensity measures of the methylation probes 
and indicated 22q losses affecting the SMARCB1 region 
in all poorly differentiated chordomas and the vast major-
ity of AT/RT as the only recurrent alteration (Fig. 1c and 
Supplementary Fig. 1), whereas conventional chordomas 
showed complex alterations including frequent losses 
of chromosomes 14q (10/14; 71 %), 3p (9/14; 64 %), 1p 
(8/14; 57 %) and 13q (7/14; 50 %) as well as chromo-
some 7q gains (7/14; 50 %). Heterozygous or homozygous 
deletions affecting the SMARCB1 region were confirmed 
on FISH and/or MLPA (4/7 and 2/7 poorly differentiated 
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Fig. 1  Molecular profiling of poorly differentiated chordoma ver-
sus conventional chordoma and AT/RT. Unsupervised clustering 
of methylation profiles of 52 samples using the 5000 most variable 
probes (a), immunohistochemistry for brachyury and SMARCB1 
(b) as well as copy number alterations derived from 450k data (c) of 
seven poorly differentiated chordomas and one recurrence (I: primary 
tumor, II: recurrence), 14 conventional chordomas and AT/RT of the 
molecular subgroups TYR, SHH and MYC (n = 10 each). N/A no 
material available for staining
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chordomas, respectively), while SMARCB1 point mutations 
were absent on sequencing (0/7 cases).
Our data confirm the detrimental prognosis of poorly 
differentiated chordomas and clearly demonstrate that 
poorly differentiated chordoma can be reliably separated 
from conventional chordoma and AT/RT by a distinct meth-
ylation profile, which may be diagnostically helpful in 
difficult cases. Whereas conventional chordomas showed 
complex copy number alterations as described previously 
[5], poorly differentiated chordomas mainly displayed 
isolated losses affecting the SMARCB1 region in 22q11 
as encountered in AT/RT. The finding that SMARCB1 was 
inactivated in poorly differentiated chordomas by dele-
tions rather than point mutations is in line with previous 
observations [10] and has been also described in other non-
rhabdoid SMARCB1-deficient soft tissue tumors such as 
epithelioid sarcoma [8]. It remains to be determined, how 
different types of SMARCB1 mutations result in a hetero-
geneous group of tumors, which may well involve differ-
ent cells of origin, different developmental stages, and a 
diverse genetic or epigenetic background in which these 
mutations occur. Given the relatively low number of cases 
examined, further prospective molecular studies would be 
highly desirable.
In conclusion, poorly differentiated SMARCB1-negative 
chordoma represents a molecularly distinct entity with dis-
mal prognosis.
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